Impact of partial bivalent HPV vaccination on vaccine-type infection: a population-based analysis

Kate Cuschieri, Kimberley Kavanagh, Catherine Moore, Ramya Bhatia, John Love, Kevin G Pollock

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background: Data on the effectiveness of 1 dose of HPV vaccine are lacking, particularly in population-based settings. Data from a national HPV immunisation catch-up programme of 14-18 year old girls were used to assess the effectiveness of < 3 doses of the bivalent vaccine on vaccine-type and cross reactive-type HPV infection. Methods: Cervical samples from women attending for their first cervical smear which had been genotyped for HPV as part of a longitudinal HPV surveillance programme were linked to immunisation records to establish the number of vaccine doses (0,1,2,3) administered. Vaccine effectiveness (VE) adjusted for deprivation and age at first dose, was assessed for prevalent HPV 16/18 and HPV 31/33/45 infection.Results: VE for prevalent HPV 16/18 infection associated with 1, 2 and 3 doses was 48.2% (95% CI 16.8-68.9), 54.8% (95% CI 30.7-70.8) and 72.8% (95% CI 62.8-80.3). Equivalent VE for prevalent HPV 31/33/45 infection was -1.62% (95% CI -85.1 – 45.3), 48.3 % (95% CI 7.6 -71.8) and 55.2 % (95% CI 32.6-70.2).Conclusion: Consistent with recent aggregated trial data, we demonstrate the potential effectiveness of even one dose of HPV vaccine on vaccine type infection. Given that these women were immunised as part of a catch-up campaign, the VE observed in this study is likely to be an underestimate of what will occur in girls vaccinated at younger ages. Further population-based studies which look at the clinical efficacy of one dose schedules arewarranted.
LanguageEnglish
Pages1261-1264
Number of pages4
JournalBritish Journal of Cancer
Volume114
Issue number11
DOIs
Publication statusPublished - 24 May 2016

Fingerprint

Vaccination
Vaccines
Infection
Population
Human papillomavirus 31
Papillomavirus Vaccines
Human papillomavirus 18
Human papillomavirus 16
Immunization
Vaginal Smears
Appointments and Schedules

Keywords

  • HPV
  • Scotland
  • vaccine

Cite this

Cuschieri, Kate ; Kavanagh, Kimberley ; Moore, Catherine ; Bhatia, Ramya ; Love, John ; Pollock, Kevin G. / Impact of partial bivalent HPV vaccination on vaccine-type infection : a population-based analysis. In: British Journal of Cancer. 2016 ; Vol. 114, No. 11. pp. 1261-1264.
@article{8258d7528f1c4caa91ad190eeb75c931,
title = "Impact of partial bivalent HPV vaccination on vaccine-type infection: a population-based analysis",
abstract = "Background: Data on the effectiveness of 1 dose of HPV vaccine are lacking, particularly in population-based settings. Data from a national HPV immunisation catch-up programme of 14-18 year old girls were used to assess the effectiveness of < 3 doses of the bivalent vaccine on vaccine-type and cross reactive-type HPV infection. Methods: Cervical samples from women attending for their first cervical smear which had been genotyped for HPV as part of a longitudinal HPV surveillance programme were linked to immunisation records to establish the number of vaccine doses (0,1,2,3) administered. Vaccine effectiveness (VE) adjusted for deprivation and age at first dose, was assessed for prevalent HPV 16/18 and HPV 31/33/45 infection.Results: VE for prevalent HPV 16/18 infection associated with 1, 2 and 3 doses was 48.2{\%} (95{\%} CI 16.8-68.9), 54.8{\%} (95{\%} CI 30.7-70.8) and 72.8{\%} (95{\%} CI 62.8-80.3). Equivalent VE for prevalent HPV 31/33/45 infection was -1.62{\%} (95{\%} CI -85.1 – 45.3), 48.3 {\%} (95{\%} CI 7.6 -71.8) and 55.2 {\%} (95{\%} CI 32.6-70.2).Conclusion: Consistent with recent aggregated trial data, we demonstrate the potential effectiveness of even one dose of HPV vaccine on vaccine type infection. Given that these women were immunised as part of a catch-up campaign, the VE observed in this study is likely to be an underestimate of what will occur in girls vaccinated at younger ages. Further population-based studies which look at the clinical efficacy of one dose schedules arewarranted.",
keywords = "HPV, Scotland, vaccine",
author = "Kate Cuschieri and Kimberley Kavanagh and Catherine Moore and Ramya Bhatia and John Love and Pollock, {Kevin G}",
year = "2016",
month = "5",
day = "24",
doi = "10.1038/bjc.2016.97",
language = "English",
volume = "114",
pages = "1261--1264",
journal = "British Journal of Cancer",
issn = "0007-0920",
number = "11",

}

Impact of partial bivalent HPV vaccination on vaccine-type infection : a population-based analysis. / Cuschieri, Kate; Kavanagh, Kimberley; Moore, Catherine; Bhatia, Ramya; Love, John ; Pollock, Kevin G.

In: British Journal of Cancer, Vol. 114, No. 11, 24.05.2016, p. 1261-1264.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Impact of partial bivalent HPV vaccination on vaccine-type infection

T2 - British Journal of Cancer

AU - Cuschieri, Kate

AU - Kavanagh, Kimberley

AU - Moore, Catherine

AU - Bhatia, Ramya

AU - Love, John

AU - Pollock, Kevin G

PY - 2016/5/24

Y1 - 2016/5/24

N2 - Background: Data on the effectiveness of 1 dose of HPV vaccine are lacking, particularly in population-based settings. Data from a national HPV immunisation catch-up programme of 14-18 year old girls were used to assess the effectiveness of < 3 doses of the bivalent vaccine on vaccine-type and cross reactive-type HPV infection. Methods: Cervical samples from women attending for their first cervical smear which had been genotyped for HPV as part of a longitudinal HPV surveillance programme were linked to immunisation records to establish the number of vaccine doses (0,1,2,3) administered. Vaccine effectiveness (VE) adjusted for deprivation and age at first dose, was assessed for prevalent HPV 16/18 and HPV 31/33/45 infection.Results: VE for prevalent HPV 16/18 infection associated with 1, 2 and 3 doses was 48.2% (95% CI 16.8-68.9), 54.8% (95% CI 30.7-70.8) and 72.8% (95% CI 62.8-80.3). Equivalent VE for prevalent HPV 31/33/45 infection was -1.62% (95% CI -85.1 – 45.3), 48.3 % (95% CI 7.6 -71.8) and 55.2 % (95% CI 32.6-70.2).Conclusion: Consistent with recent aggregated trial data, we demonstrate the potential effectiveness of even one dose of HPV vaccine on vaccine type infection. Given that these women were immunised as part of a catch-up campaign, the VE observed in this study is likely to be an underestimate of what will occur in girls vaccinated at younger ages. Further population-based studies which look at the clinical efficacy of one dose schedules arewarranted.

AB - Background: Data on the effectiveness of 1 dose of HPV vaccine are lacking, particularly in population-based settings. Data from a national HPV immunisation catch-up programme of 14-18 year old girls were used to assess the effectiveness of < 3 doses of the bivalent vaccine on vaccine-type and cross reactive-type HPV infection. Methods: Cervical samples from women attending for their first cervical smear which had been genotyped for HPV as part of a longitudinal HPV surveillance programme were linked to immunisation records to establish the number of vaccine doses (0,1,2,3) administered. Vaccine effectiveness (VE) adjusted for deprivation and age at first dose, was assessed for prevalent HPV 16/18 and HPV 31/33/45 infection.Results: VE for prevalent HPV 16/18 infection associated with 1, 2 and 3 doses was 48.2% (95% CI 16.8-68.9), 54.8% (95% CI 30.7-70.8) and 72.8% (95% CI 62.8-80.3). Equivalent VE for prevalent HPV 31/33/45 infection was -1.62% (95% CI -85.1 – 45.3), 48.3 % (95% CI 7.6 -71.8) and 55.2 % (95% CI 32.6-70.2).Conclusion: Consistent with recent aggregated trial data, we demonstrate the potential effectiveness of even one dose of HPV vaccine on vaccine type infection. Given that these women were immunised as part of a catch-up campaign, the VE observed in this study is likely to be an underestimate of what will occur in girls vaccinated at younger ages. Further population-based studies which look at the clinical efficacy of one dose schedules arewarranted.

KW - HPV

KW - Scotland

KW - vaccine

U2 - 10.1038/bjc.2016.97

DO - 10.1038/bjc.2016.97

M3 - Article

VL - 114

SP - 1261

EP - 1264

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 11

ER -